Pharmaceuticals company Indoco Remedies announced Q1FY25 results: During Q1FY25, revenues of Indoco Remedies are at Rs 3,942 million, as against Rs 4,132 million, same quarter last year. EBIDTA to net sales for the quarter is 13.1% at Rs 516 million, compared to 15.2% at Rs 629 million, same quarter last year. Profit After Tax to net sales is 3.8% at Rs 150 million, compared to 6.3% at Rs 259 million, same quarter last year. Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies said, “From licensing out products to front-ending in the US and from a 95% ethically driven domestic business, to selectively chosen products in OTC business, we are undergoing significant strategic transitions at Indoco. Our performance this quarter is reflective of these various strategic moves and I am confident that these will give Indoco a major gain in the long term.” Result PDF
Conference Call with Indoco Remedies Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Indoco Remedies announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: During the Q4FY24, revenues of Indoco Remedies grew by 1.7% at Rs 4,351 million, as against Rs 4,280 million, same quarter last year. EBIDTA to net sales for the quarter is 13.2% at Rs 574 million, compared to 15.0% at Rs 642 million, same quarter last year. Profit After Tax to net sales is 8.6% at Rs 376 million, compared to 5.9% at Rs 254 million, same quarter last year. FY24 Financial Highlights: For the year, revenues grew by 7.6% at Rs 17,619 million, as against Rs 16,381 million, same period last year. EBIDTA to net sales for the period is 14.6% at Rs 2,580 million, compared to 17.4% at Rs 2,849 million, same period last year. Profit After Tax to net sales is 6.6% at Rs 1,166 million, compared to 8.6% at Rs 1,414 million, same period last year. Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, “Indoco is set to take a big leap based on the various strategic decisions taken during this year. We are optimistic to improve our performance in the coming quarters.” Result PDF